엑사젠 (XGN) 주가

엑사젠(XGN)는 NASDAQ에 상장된 Healthcare · Diagnostics & Research 기업입니다. 현재가 $6.66 (+1.22%), 시가총액 $0.09B, 52주 범위 $2.65 ~ $11.96.

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by

핵심 지표

• 현재가: $6.66 (+1.22%)
• 시가총액: $0.09B
• 52주 최저~최고: $2.65 ~ $11.96
• 섹터: Healthcare
• 산업: Diagnostics & Research
• 거래소: NASDAQ

엑사젠의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

엑사젠 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.6667

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 4.07
• 순이익률: -0.29%
• 영업이익률: -0.20%

자주 묻는 질문